ID   BICR 78
AC   CVCL_2315
SY   BICR-78; BICR78; Beatson Institute for Cancer Research 78
DR   CLO; CLO_0009944
DR   EFO; EFO_0006543
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 837
DR   BioSample; SAMN03473146
DR   cancercelllines; CVCL_2315
DR   CancerTools; 152849
DR   Cell_Model_Passport; SIDM00501
DR   Cosmic; 848755
DR   Cosmic; 1995346
DR   Cosmic-CLP; 1240122
DR   DepMap; ACH-001332
DR   ECACC; 04072111
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1240122
DR   GEO; GSM827457
DR   GEO; GSM1669624
DR   LINCS_LDP; LCL-1205
DR   PharmacoDB; BICR78_100_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2315
DR   Wikidata; Q54796540
DR   Ximbio; 152849
RX   PubMed=7646764;
RX   PubMed=9150362;
RX   PubMed=10523844;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,29:02; B*44:03,44:03; C*05:01,16:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-7del; Zygosity=Homozygous (PubMed=20215515).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln38Ter (c.112C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=9150362; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro177Leu (c.530C>T); ClinVar=VCV000406583; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.26%; Native American=1.14%; East Asian, North=2.29%; East Asian, South=0%; South Asian=0.91%; European, North=63.51%; European, South=28.89% (PubMed=30894373).
CC   Derived from site: In situ; Oral cavity, alveolar ridge; UBERON=UBERON_0004102.
ST   Source(s): Cosmic-CLP; DepMap; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 13,19
ST   D21S11: 33.2
ST   D3S1358: 18
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 19
ST   Penta D: 10
ST   Penta E: 11,13
ST   TH01: 6,9.3
ST   TPOX: 9,10
ST   vWA: 15,16
DI   NCIt; C170774; Alveolar ridge squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 37
//
RX   PubMed=7646764; DOI=10.1002/mc.2940130408;
RA   Edington K.G., Loughran O.P., Berry I.J., Parkinson E.K.;
RT   "Cellular immortality: a late event in the progression of human
RT   squamous cell carcinoma of the head and neck associated with p53
RT   alteration and a high frequency of allele loss.";
RL   Mol. Carcinog. 13:254-265(1995).
//
RX   PubMed=9150362; DOI=10.1038/sj.onc.1201028;
RA   Loughran O.P., Clark L.J., Bond J., Baker A., Berry I.J., Edington K.G.,
RA   Ly I.-S., Simmons R., Haw R., Black D.M., Newbold R.F.,
RA   Parkinson E.K.;
RT   "Evidence for the inactivation of multiple replicative lifespan genes
RT   in immortal human squamous cell carcinoma keratinocytes.";
RL   Oncogene 14:1955-1964(1997).
//
RX   PubMed=10523844; DOI=10.1038/sj.onc.1202957;
RA   Agochiya M., Brunton V.G., Owens D.W., Parkinson E.K., Paraskeva C.,
RA   Keith W.N., Frame M.C.;
RT   "Increased dosage and amplification of the focal adhesion kinase gene
RT   in human cancer cells.";
RL   Oncogene 18:5646-5653(1999).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//